Mergers & acquisitions
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
Shares of Halyard Health are up more than 12 percent after the company announced it was selling its S&IP business to Owens & Minor for $710M.
Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line.
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa.
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Shares of Neos Therapeutics have soared more than 38 percent this morning after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287M.
Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.
PRESS RELEASES